TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Bogavac-Stanojević, Nataša
AU  - Ilias, Ioannis
AU  - Silva-Nunes, José
AU  - Pantea Stoian, Anca
AU  - Janez, Andrej
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4100
AB  - Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.
PB  - MDPI
T2  - Pharmaceutics
T1  - Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
VL  - 14
IS  - 4
DO  - 10.3390/pharmaceutics14040825
ER  - 

@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Bogavac-Stanojević, Nataša and Ilias, Ioannis and Silva-Nunes, José and Pantea Stoian, Anca and Janez, Andrej and Rizzo, Manfredi",
year = "2022",
abstract = "Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL",
volume = "14",
number = "4",
doi = "10.3390/pharmaceutics14040825"
}

Vekić, J., Zeljković, A., Stefanović, A., Bogavac-Stanojević, N., Ilias, I., Silva-Nunes, J., Pantea Stoian, A., Janez, A.,& Rizzo, M.. (2022). Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics
MDPI., 14(4).
https://doi.org/10.3390/pharmaceutics14040825

Vekić J, Zeljković A, Stefanović A, Bogavac-Stanojević N, Ilias I, Silva-Nunes J, Pantea Stoian A, Janez A, Rizzo M. Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics. 2022;14(4).
doi:10.3390/pharmaceutics14040825 .

Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Bogavac-Stanojević, Nataša, Ilias, Ioannis, Silva-Nunes, José, Pantea Stoian, Anca, Janez, Andrej, Rizzo, Manfredi, "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL" in Pharmaceutics, 14, no. 4 (2022),
https://doi.org/10.3390/pharmaceutics14040825 . .

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Cicero, Arrigo F. G.
AU  - Janez, Andrej
AU  - Stoian, Anca Pantea
AU  - Sonmez, Alper
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4063
AB  - Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.
PB  - MDPI
T2  - Medicina
T1  - Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL
VL  - 58
IS  - 2
SP  - 299
DO  - 10.3390/medicina58020299
ER  - 

@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Cicero, Arrigo F. G. and Janez, Andrej and Stoian, Anca Pantea and Sonmez, Alper and Rizzo, Manfredi",
year = "2022",
abstract = "Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.",
publisher = "MDPI",
journal = "Medicina",
title = "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL",
volume = "58",
number = "2",
pages = "299",
doi = "10.3390/medicina58020299"
}

Vekić, J., Zeljković, A., Cicero, A. F. G., Janez, A., Stoian, A. P., Sonmez, A.,& Rizzo, M.. (2022). Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina
MDPI., 58(2), 299.
https://doi.org/10.3390/medicina58020299

Vekić J, Zeljković A, Cicero AFG, Janez A, Stoian AP, Sonmez A, Rizzo M. Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina. 2022;58(2):299.
doi:10.3390/medicina58020299 .

Vekić, Jelena, Zeljković, Aleksandra, Cicero, Arrigo F. G., Janez, Andrej, Stoian, Anca Pantea, Sonmez, Alper, Rizzo, Manfredi, "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL" in Medicina, 58, no. 2 (2022):299,
https://doi.org/10.3390/medicina58020299 . .